Purchase this article with an account.
Pavel Nemec, Jan Ernest, Leos Rejmont, Zaneta Benesova, Libor Hejsek; Endophthalmitis Following Intravitreal Injection Of Anti-vascular Endothelial Growth Factor (anti-vegf) Agents. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1697.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the incidence of endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents and to comment results of laboratory specification and treatment.
A total of 2,274 intravitreal anti-VEGF injections (1,213 pegaptanib, 1,061 ranibizumab) were performed from 2007 to 2010. The injections were performed as an out-patient procedure with use of povidone-iodine as a part of preinjection preparation. Preinjection topical antibiotics, sterile environment, sterile gloves and postinjection topical antibiotics were used.
There were eight cases of endophthalmitis, six cases following pegaptanib injection and two cases following ranibizumab injection. Only one patient regained her preinjection visual acuity. The incidence of endophthalmitis was 0,35%. There was no difference in the incidence of endophthalmitis between pegaptanib and ranibizumab (P = 0.6).
Although there is no consensus regarding the intravitreal injection procedure technique, the incidence of endophthalmitis was low in a large series of injected patients in a comparison with results reported in clinical trials where much more extensive preinjection preparation was mandated. The most frequent pathogen was found Streptococcus epidermidis (75% cases). We found no difference in the endophthalmitis risk of patients receiving pegaptanib as compared with ranibizumab.
This PDF is available to Subscribers Only